All updates
All updates
today 46中文产业新闻Chinese source评分6565
文献与产业新闻评分5353 Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
顶刊论文（社媒热度）精选评分7373 Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease.
文献与产业新闻评分4747 Intercepting pancreatic cancer with a vaccine
文献与产业新闻评分2222 Balanced fluid no better than saline for children with septic shock
文献与产业新闻评分3434 STAT+: Experts scrutinize Huidagene’s disclosures after patient death
文献与产业新闻精选评分7373 Moderna, Merck Phase III win opens door to personalized neoantigen vaccines
文献与产业新闻评分3535 Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill
中文产业新闻精选Chinese source评分7474 阿斯利康 PD-1/CTLA-4 双抗 Volrustomig 一线 NSCLC III 期因中期分析被终止
中文产业新闻精选Chinese source评分7979 Amylyx 全球首创 GLP-1 抑制剂 avexitide III 期 LUCIDITY 研究达到主要终点
中文产业新闻Chinese source评分6464 百利天恒 EGFR/HER3 双抗 ADC iza-bren 三期试验在 EGFR-TKI 耐药 NSCLC 达到 PFS 主要终点
中文产业新闻精选Chinese source评分6868 DURAVYU 治疗湿性 AMD 三期 LUGANO 未达非劣效主要终点
中文产业新闻精选Chinese source评分7474 Amylyx avexitide 三期达主要终点，严重低血糖发作风险降低55%
顶刊论文（社媒热度）精选评分6464 Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia: The ZIPS-2 Randomized Clinical Trial.
文献与产业新闻评分3636 Dissecting Chinese trial strategy in wake of deaths
文献与产业新闻精选评分7474 STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
文献与产业新闻评分5050 STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
文献与产业新闻评分5656 Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial
文献与产业新闻评分3232 Waking from the nightmare of PTSD
文献与产业新闻精选评分7676 Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
顶刊论文（社媒热度）精选评分7272 Finerenone in Persons with Chronic Kidney Disease without Diabetes.
顶刊论文（社媒热度）精选评分8888 Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.
中文产业新闻精选Chinese source评分7070 阿斯利康终止 PD-1/CTLA-4 双抗 Volrustomig 三期 eVOLVE-Lung02 试验
中文产业新闻精选Chinese source评分6969 EyePoint 长效眼科新药 DURAVYU 湿性 AMD 三期 LUGANO 试验失败 股价大跌 67%
中文产业新闻Chinese source评分6060 百利天恒EGFR×HER3双抗ADC伦康依隆妥单抗又一III期研究达主要终点
中文产业新闻Chinese source评分6666 阿斯利康/第一三共：Enhertu一线治疗非小细胞肺癌III期DESTINY-Lung04取得高水平阳性结果
中文产业新闻精选Chinese source评分7878 argenx 皮下注射 Vyvgart Hytrulo 治疗成人自身免疫性肌炎 2/3 期 ALKIVIA 试验达主要终点
中文产业新闻Chinese source评分6464 Argenx涨16%，FcRn抑制剂efgartigimod自身免疫性肌炎三期临床成功
中文产业新闻Chinese source评分6161 伏罗尼布wAMD三期临床失败，EyePoint股价大跌67%，贝达药业持大中华区权益
顶刊论文（社媒热度）精选评分6060 First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.
文献与产业新闻评分5353 Biokin bispecific ADC iza-bren hits goal in lung cancer trial, boosting case for BMS’ global test
文献与产业新闻精选评分8484 STAT+: Amylyx endocrine drug succeeds in pivotal study
文献与产业新闻评分3737 STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
顶刊论文（社媒热度）精选评分6262 Self-Directed vs Clinician-Delivered Cognitive Behavioral Therapy for Chronic Pain: A Randomized Clinical Trial.
文献与产业新闻精选评分7070 STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
文献与产业新闻精选评分7272 Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
顶刊论文（社媒热度）评分5757 One-Year Outcomes After Endovascular Treatment for Large Acute Ischemic Stroke: The TESLA Randomized Clinical Trial.
顶刊论文（社媒热度）精选评分8181 Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
文献与产业新闻精选评分7373 EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
文献与产业新闻精选评分6666 Pivotal misses punish EyePoint and Tenax